JAK3 and cancer: Although the cohort is too small to support statistical analyses, the strong activation of the STAT5 pathway exerted by JAK3-V722I, together with the identification of the same variant as a somatic event in several cancers suggests that this mutation, when present as a germline variant, may associate with an increased risk of cancer evolution.